References
- De Lavallade H, Apperley JF, Khorashad JS, et al Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3563.
- Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.
- Alfonso QC, Hagop MK, O'Brien S, et al Association of pleural effusion and bleeding in patients with chronic myelogenous leukemia receiving dasatinib. Blood 2008;112(Suppl. 1): (Abstract 2112).
- Talpaz M, Shah NP, Kantarjian H, et al Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531–2541.
- Quintas-Cardama A, Kantarjian H, Jones D, et al Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007;109:497–499.
- Sinthiya P, Hugues de L, Dragana M, et al Pleural effusions associated with use of dasatinib in chronic myeloid leukemia may have an auto-immune pathogenesis. Blood 2007;110(Suppl. 1): (Abstract 2945).